Human pandemic H1N1 2009 influenza virus causes significant morbidity and mortality with severe acute lung injury due to the excessive inflammatory reaction, even with neuraminidase inhibitor use. The anti-inflammatory effect of anti-high-mobility group box-1 (HMGB1) monoclonal antibody (mAb) against influenza pneumonia has been reported. In this study, we evaluated the combined effect of anti-HMGB1 mAb and peramivir against pneumonia induced by influenza A (H1N1) virus in mice. Nine-week-old male C57BL/6 mice were inoculated with H1N1 and treated with intramuscularly administered peramivir at 2 and 3 days post-infection (dpi). The anti-HMGB1 mAb or a control mAb was administered at 2, 3, and 4 dpi. Survival rates were assessed, and lung lavage and pathological analyses were conducted at 5 and 7 dpi. The combination of peramivir with the anti-HMGB1 mAb significantly improved survival rate whereas the anti-HMGB1 mAb alone did not affect virus proliferation in the lungs. This combination therapy also significantly ameliorated histopathological changes, neutrophil infiltration, and macrophage aggregation by inhibiting HMGB1, inflammatory cytokines, and oxidative stress. Fluorescence immunostaining showed that the anti-HMGB1 mAb inhibited HMGB1 translocation from type I alveolar epithelial cells. In summary, combining anti-HMGB1 with conventional anti-influenza therapy might be useful against severe influenza virus infection.
factors. 7 Therefore, treatment with anti-inflammatory agents along with antiviral agents might be a promising strategy against severe influenza.
8
The inflammatory role of high-mobility group box-1 (HMGB1) has been recently investigated in influenza infection. 8 HMGB1 is a highly conserved non-histone chromosomal protein and originally identified as a DNA-binding protein. HMGB1 sustains nucleosome structure and regulates gene transcription. 9 It is either actively released by activated immune cells or passively released from damaged/necrotic cells. The extracellular HMGB1 can act as a proinflammatory cytokine-like mediator. HMGB1 has been reported to be involved in the pathogenesis of a wide range of diseases, including sepsis, traumatic brain injury, and several viral infections. 9, 10 The effect of anti-HMGB1 monoclonal antibody (mAb) treatment in a murine model of influenza-induced pneumonia 11 and brain edema 12 has been reported. In the pneumonia model, anti-HMGB1 mAb improved the survival rate significantly and ameliorated lung damage without an anti-influenza drug.
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The US Centers for Disease Control and Prevention and the World Health Organization recommend NAI use for the treatment of seasonal and pandemic influenza, 13, 14 and treatment with NAI is the main strategy for managing influenza infection. 2 In severe influenza cases that cannot be treated with NAI alone, combination treatment with an anti-HMGB1 mAb represents an interesting treatment option. In the present study, a severe influenza murine model was developed and the combined effect of an anti-HMGB1 mAb and peramivir 15 (intravenous NAI) treatment was examined.
Furthermore, the role of the anti-HMGB1 mAb in the translocation of HMGB1 from type I alveolar epithelial cells (AECI) was investigated. 
| MATERIALS AND METHODS

| Ethical approval
| Establishment of NAI-insufficient influenza pneumonia mouse model
Nine-week-old male C57BL/6 mice were obtained from Charles River
Laboratories (Yokohama, Japan) and were housed in a specific pathogen-free animal facility controlled at 25°C with a 12-hour light/ dark cycle. They were fed a regular pellet diet (Oriental MF; Oriental Yeast, Ltd, Tokyo, Japan) and given ad libitum access to drinking water.
The influenza virus strain A/Puerto Rico/8/34 (H1N1) used in this study is a highly virulent, mouse-adapted virus, which was prepared as described previously. 11 An A/Puerto Rico/8/34 (H1N1) infection is treatable with NAI. 16 The 50% mouse lethal dose (MLD 50 ) was determined as 100 plaque-forming units (pfu). After being anesthetized with intraperitoneal ketamine (50 mg/kg) and pentobarbital (30 mg/kg), the mice were infected intranasally with 1500 pfu (15 MLD 50 ) of H1N1 in 25 μL of sterile phosphate-buffered saline (PBS). Then, the mice were allowed to recover. We defined the day of the virus infection as 0 days post-infection (dpi). Peramivir (RAPIACTA  ® ; 10 mg/kg) (Shionogi & Co, Ltd) was administered intramuscularly at 2 and 3 dpi in peramivir-treated groups.
After infection with the virus, the mice were randomly divided into four groups: (1) class-matched control mAb only group; (2) anti-HMGB1 mAb only group; (3) peramivir and class-matched control mAb-treated group; (4) peramivir and anti-HMGB1 mAb-treated
group. An anti-HMGB1 mAb (#10-22, IgG2a subclass; 7.5 mg/kg) or a class-matched control Ab (anti-keyhole limpet hemocyanin) was given intravenously through the caudal vein at 2, 3, and 4 dpi after the virus infection in accordance with the treatment schedule for each group. These mAbs were produced as described previously.
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The dose of anti-HMGB1 mAb was considered sufficient.
| Survival rate analysis
The survival rates of all mice, including those administered the anti-HMGB1 mAb or control mAb without peramivir, were evaluated until 28 dpi. Our influenza pneumonia model showed severe lung injury;
thus, we could not collect favorable samples from the groups without peramivir treatment (Groups 1 and 2 described above). Therefore, the following experiments were performed among the groups with peramivir treatment (Groups 3 and 4 described above) to assess the additional impact of anti-HMGB1 mAb treatment.
| Pathological analysis
After H1N1 inoculation, pathological analyses were conducted at 5 and 7 dpi. Animals were subjected to euthanasia before collecting their blood and bronchoalveolar lavage fluid (BALF) for measuring cytokines/chemokines and hydroperoxides.
The severity of the lung injury was scored as described previously. 18 Briefly, the following four readily identifiable pathological Bronchoalveolar lavage was performed as reported earlier. 19 Briefly, the right lung was lavaged with 1 mL of cold PBS after the ligation of the left main bronchus. The collected BALF was spun down at 2000 rpm for 10 minutes at 4°C, and its supernatant was kept at −80°C for the measurement of cytokines. A total neutrophil count in the BALF was performed using a 200-μL pellet aliquot. Cell differentiation was evaluated using Diff-Quick staining (Sysmex, Kobe, Hyogo, Japan) for at least 200 neutrophils on a smear prepared from the pellet. The total number of neutrophils and macrophages in BALF was measured and expressed per animal.
| Immunohistochemistry
Immunohistochemical staining was conducted as previously The hydroperoxide level (whole oxidant capacity of plasma against N,N-diethyl-p-phenylenediamine in an acidic buffer) in plasma was measured using a free radical elective evaluator (FREE Carrio Duo;
Diacron, Grosseto, Italy). It has been established that one measurement unit (CARR U) corresponds to 0.08 mg/dL hydrogen peroxide. 20 
| Statistics
Data are presented as the mean ± standard error of the mean. All data were compared using the Mann-Whitney U-test or log-rank test where appropriate. The statistical analysis was conducted using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA).
3 | RESULTS
| Anti-HMGB1 mAb improves survival by inhibiting TLR4 in the lung
Most mice without peramivir treatment died at 7 and 8 dpi ( Figure 1A ).
A total of 90.9% of the mice that were treated with a combination of the anti-HMGB1 mAb and peramivir survived, whereas only 45.5% of F I G U R E 1 Effects of peramivir and anti-high-mobility group box 1 (anti-HMGB1) mAb treatment on survival, viral load, and toll-like receptor 4 (TLR4) level after H1N1 inoculation. A, Survival rate: one mouse (9.1%) in the peramivir+anti-HMGB1 mAb-treated group (n = 11) died, and six mice (54.5%) in the peramivir+control-IgG-treated group (n = 11) died. *P < 0.05 by the log-rank (Mantel-Cox) test. No mice survived without peramivir. B, Viral load in the lung: there were no significant differences in viral load at 5 or 7 dpi. Data represent the mean ± SEM of 11 mice. *P < 0.05 by the Mann-Whitney U-test. C, The anti-HMGB1 mAb-treated mice had lower levels of TLR4 in the BALF than control mice at 5 dpi. The dotted line describes the normal basal level. Data show the mean ± SEM of 11 mice. BALF, bronchoalveolar lavage fluid; mAb, monoclonal antibody the control mice (control mAb+peramivir) survived. Because the body weight of the mice was the lowest at 7 dpi, 5, and 7 dpi were chosen as time points for subsequent analysis.
No significant difference of the viral copies in the lung at either 5 or 7 dpi was detected between the anti-HMGB1 mAb-treated and control mAb-treated mice ( Figure 1B) . The levels of TLR4 in the BALF at 5 dpi were lower in the anti-HMGB1 mAb-treated mice than those in the control mice ( Figure 1C ).
| Anti-HMGB1 mAb alleviates lung damage
The histopathological patterns observed in the anti-HMGB1 mAbtreated group differed from those in the control group (Figure 2 ). The control mice showed the infiltration of inflammatory cells into the alveoli and the interstitium, diffuse edema, and hemorrhage. These histopathological changes were attenuated in the anti-HMGB1 mAbtreated mice, which led to lower lung injury scores than those in the control mice at 5 and 7 dpi.
| Anti-HMGB1 mAb inhibits the infiltration of neutrophils and macrophages to the lung
The anti-HMGB1 mAb-treated mice had significantly lower counts of neutrophils and macrophages in the BALF than the control mice at 5 dpi, whereas these counts were not significantly different from control values at 7 dpi (Figure 3 ). These changes could also be observed on immunostained images.
| Anti-HMGB1 mAb inhibits the translocation of HMGB1 from AECI
To investigate the origin of HMGB1 in the BALF, lung cells, including AECI and AECII, and bronchial epithelial cells were immunostained.
The translocation of HMGB1 from the nucleus to the cytosol was observed in AECI (white arrowhead in Figure 4B ) whereas anti-HMGB1 mAb treatment suppressed the HMGB1 release (white arrows in Figure 4C ). No apparent HMGB1 release was observed from AECII or bronchial epithelial cells (data not shown).
3.5 | Anti-HMGB1 mAb controls cytokine/chemokine responses and systemic oxidative stress
The cytokine/chemokine measurement results showed that the levels of TNF-α, IL-6, G-CSF, CXCL1, MCP1, CCL3, and RANTES in the BALF at 5 dpi were significantly lower in the anti-HMGB1 mAbtreated group than those in the control group, whereas these levels did not significantly differ between the same groups at 7 dpi ( Figure 5A ). The CXCL10 level in the BALF at 5 dpi was lower in the anti-HMGB1 mAb-treated group than that in the control group, but the difference was not statistically significant (P = 0.07).
The hydroperoxide levels in the plasma at 5 dpi ( Figure 5B ) were also significantly lower in the anti-HMGB1 mAb-treated group than those in the control group, whereas these hydroperoxide levels did not significantly differ between the two groups at 7 dpi.
| DISCUSSION
An exaggerated innate immune response has been recognized as a major complication in severe influenza cases, accompanied with massive neutrophil infiltration to the lung due to elevated levels of inflammatory cytokines and chemokines. 4, 21 Both anti-inflammatory therapy and antiviral treatment are important for severe influenza.
Therefore, we aimed to evaluate the additional effect of an anti-HMGB1 mAb therapy in the mouse model of NAI-insufficient influenza. The combination therapy of an anti-HMGB1 mAb and peramivir improved the survival rate of mice with influenza-induced pneumonia without any effect against the propagation of influenza F I G U R E 2 Effects of peramivir and anti-high-mobility group box 1 (HMGB1) mAb treatment on lung histology after H1N1 inoculation. A, Hematoxylin and eosin staining of lung tissue samples at 5 and 7 dpi. These are representative of four independent experiments. Peramivir +control-IgG group lung tissue showed diffuse edema and hemorrhage in alveoli and the interstitium. Destruction of the alveolar structure was detected. These histopathological changes were attenuated in the peramivir+anti-HMGB1 mAb group. B, Lung injury scores: data show the mean ± SEM of four independent experiments; * P < 0.05 by the Mann-Whitney U-test. mAb, monoclonal antibody virus. Hence, the improvement in the survival rate might be due to the anti-inflammatory effect of the anti-HMGB1 mAb but not due to the inhibition of virus propagation.
TLR4 is one of the major HMGB1 receptors. 22 In this study, anti- 
Effects of peramivir and anti-high-mobility group box 1 (anti-HMGB1) mAb treatment on cytokines and chemokines in the BALF and hydroperoxides in plasma after H1N1 inoculation. A, Effects of peramivir and anti-HMGB1 mAb treatment on cytokines and chemokines in the BALF after H1N1 inoculation. Data show the mean ± SEM of 6 to 8 mice. The dotted line describes the normal basal level. TNF-α, IL-6, and MCP1 were not detectable in the normal mice; *P < 0.05, **P < 0.01 by the Mann-Whitney U-test. B, Effects of peramivir and anti-HMGB1 mAb treatment on hydroperoxides in the plasma after H1N1 inoculation. Data describe the mean ± SEM of 10 to 11 mice. The dotted line shows the normal basal level; **P < 0.01 by the Mann-Whitney U-test. BALF, bronchoalveolar lavage fluid; mAb, monoclonal antibody ability to inhibit HMGB1-induced TLR4 signaling and a subsequent TLR4-dependent cytokine storm. To investigate the origin of TLR4, we performed immunohistochemical staining of TLR4 of AECI and AECII (data not shown); however, the TLR4 expression could not be visualized in this study. TLR4 expression was reported to be elevated at the ALI caused by LPS or Alarmin S100A8 especially in AECII in vitro 25, 26 ; however, there is no report that shows the expression of TLR4 in AECI and AECII with ALI in vivo. Further experiments would be necessary to explain the source of TLR4 in ALI.
In this study, anti-HMGB1 mAb and peramivir treatment inhibited the production of cytokines/chemokines, including TNF-α, IL-6, G-CSF, CXCL1, MCP1, CCL3, CXCL10, and RANTES. Reportedly, all these cytokines/chemokines are associated with the pathology of influenza. 4, 27 The levels of TNF-α and IL-6 are linked to host morbidity and mortality in influenza patients. 28 35 Inhibition of these proinflammatory cytokines is predicted to result in less infiltration of inflammatory cells to the lungs and alleviation of lung injury.
There are several anti-inflammatory agents that have been evaluated for efficacy against severe influenza using murine models, such as the commercially available TNF-α inhibitor etanercept, 28 corticosteroids,
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COX2 inhibitors, 37 a TLR4 antagonist (Eritoran), 23 and anti-HMGB1 mAb. 11 Considering that there is no reason to treat influenza without NAI in daily clinical settings, we are interested in evaluating the adjunctive effects of these agents with NAI therapy against severe influenza.
However, there have been limited studies evaluating the combination therapy. Shirey et al showed the combined effect of Eritoran and oseltamivir against influenza. While Eritoran monotherapy provided a significant degree of protection from lethality, the combined Eritoran and oseltamivir treatment showed a significant improvement of survival when the therapy initiation was delayed. 38 Zheng et al 37 showed the combined effect of a COX-2 inhibitor and zanamivir against H5N1. COX-2 inhibitors
were not as effective as monotherapy in H5N1 influenza-infected mice but they were effective when used in combination with zanamivir. Walsh et al showed the combined effect of a sphingosine analog, AAL-R, and oseltamivir against H1N1 2009. Treatment with AAL-R and oseltamivir significantly improved survival rate by limiting pulmonary injury. 39 These studies in addition to our study suggest that combination with antiviral and anti-inflammation therapies is a promising strategy against severe influenza. However, these anti-inflammatory therapies act in influenza infections by exerting immunosuppression. Moreover, our study showed that anti-HMGB1 mAb did not inhibit virus replication. Thus, when we apply these anti-inflammatory therapies with conventional therapy in the future, close follow up of patients and careful monitoring of viral load would be necessary.
In this study, we also found that anti-HMGB1 mAb and peramivir therapy ameliorated the level of hydroperoxides. This finding indicates that this combination therapy provides a broad suppression of local cytokines/chemokines and systemic oxidative stress. We have previously reported that the redox-active protein thioredoxin-1 attenuated H1N1-induced pneumonia in mice through its antioxidative properties. 19 An important role of reactive oxygen and nitrogen species as mediators in influenza virus-induced lung injury has been substantiated by previous studies; superoxide dismutase, N-monomethyl-L-arginine, or allopurinol suppressed lung injury and improved the survival rate of the infected mice. 40, 41 Further research using a multidisciplinary approach for influenza-induced pneumonia studies in appropriate animal models is therefore warranted.
Interestingly, administration of the anti-HMGB1 mAb inhibited HMGB1 translocation from AECI. Yao et al reported the translocation of HMGB1 from the nucleus to the cytoplasm in lung epithelial cells and its subsequent release into the extracellular lung space in a mouse model of cigarette smoke-induced pulmonary inflammation, which suggested the involvement of a TLR4-mediated signaling cascade. 42 Izushi et al 43 reported HMGB1 release from the nucleus to the cytosol in AECI in a lipopolysaccharide-induced ALI model.
Hirincus et al 44 reported that the H1N1 (PR8) is widely dispersed in the alveoli including in AECI and AECII. However, considering that more than 98% of the internal surface area in the rodent pulmonary alveolus is covered by AECI, 43 it is reasonable to assume that most of the inflammation-related events are associated with the AECI.
While we have shown the combined effect of NAI and anti-HMGB1 mAb in an NAI-insufficient severe influenza model, NAIresistant influenza is another issue. 45 Further research is needed to evaluate the effect of anti-HMGB1 mAb against NAI-resistant influenza. 
| CONCLUSIONS
